Spirocyclic HCV Inhibitors Targeting NS3-4A Protease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infection, particularly those targeting the NS3 serine protease, have low efficacy and significant side effects, with no effective vaccine available, and existing therapies struggle to manage HCV-associated disorders effectively.
Innovation Solution
Development of compounds that inhibit HCV NS3-4A protease activity, including spirocyclic compounds that interact with the NS3 protease and its cofactor NS4A, disrupting protein interactions essential for viral replication, thereby preventing the processing of viral polyprotein and reducing HCV RNA load.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies (interferon-α and ribavirin) are used to treat HCV infection, then HCV infection can be addressed, but the treatment has low sustained response rate and frequent side effects
Solution Approach 1:
The patent applies parameter changes by developing novel spirocyclic compounds with modified chemical structures and properties compared to existing therapies. The compounds of Formula I and Formula III represent new chemical entities with altered pharmacological parameters that aim to achieve better efficacy and reduced side effects through changes in molecular structure, potency, and selectivity parameters.
Solution Approach 2:
The patent employs composite materials by creating complex spirocyclic molecular structures that combine multiple functional groups and structural elements. The compounds integrate heterocyclic rings, spirocyclic systems, and various substituents to form composite molecular architectures that target HCV protease with enhanced specificity and reduced off-target effects.
2Productivity
If HCV infection is treated with existing therapies, then viral infection can be addressed, but the treatment efficacy is limited and side effects are frequent
Solution Approach 1:
The patent applies segmentation by designing compounds that specifically target and inhibit the NS3/4A protease function, segmenting the antiviral mechanism to focus on a critical viral enzyme. This targeted approach segments the treatment strategy from non-specific immunomodulation to specific protease inhibition, improving efficacy while reducing side effects associated with broad-spectrum therapies.
Solution Approach 2:
The spirocyclic compounds serve as intermediaries that bind to the HCV NS3/4A protease active site, mediating the inhibition of viral polyprotein processing. These compounds act as molecular intermediaries that block the protease-cofactor interaction, preventing viral replication without requiring the host immune system, thereby improving treatment reliability and reducing immun-related side effects.
3Reliability
If spirocyclic compounds are developed to inhibit HCV NS3-4A protease, then treatment efficacy can be improved, but the complexity of compound structure increases
Solution Approach 1:
The patent applies universality by designing spirocyclic core structures that can accommodate various substituents and modifications while maintaining the fundamental protease inhibition mechanism. The core spirocyclic framework serves as a universal platform that can be systematically modified to optimize potency, selectivity, and pharmacokinetic properties across a series of analogs, managing structural complexity through modular design.
Data Source
AI summary
The present application describes organic compounds of formula (I): that are useful for the treatment, prevention and/or amelioration of human diseases such as HCV and HIV.